Cargando…

Response to mRNA COVID-19 vaccination in three XLA patients

X-linked agammaglobulinemia (XLA) is an inborn error of immunity characterized by insufficient production of immunoglobulins and lack of measurable antibody response to vaccines. The rise of novel infections limits the protective effect of immunoglobulin replacement in immunodeficient patients thoug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Squire, J.D., Joshi, A.Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345887/ https://www.ncbi.nlm.nih.gov/pubmed/35934578 http://dx.doi.org/10.1016/j.vaccine.2022.07.046

Ejemplares similares

Brief review of the mRNA vaccines COVID-19
por: Vitiello, Antonio, et al.
Publicado: (2021)

Myocarditis following COVID-19 mRNA vaccination
por: Abu Mouch, Saif, et al.
Publicado: (2021)

Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients
por: Advani, Pooja, et al.
Publicado: (2021)

Humoral immune response to COVID-19 mRNA vaccination in relation to selenium status
por: Demircan, Kamil, et al.
Publicado: (2022)

Limapakgsin ixlilakkaxlan xla pulataman Veracruz xla Ignacio de la Llave
Publicado: (2012)

Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272
por: Bozzi, Giorgio, et al.
Publicado: (2021)

BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients
por: Teocchi, Marcelo A, et al.
Publicado: (2015)

New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure
por: Toljan, Karlo, et al.
Publicado: (2022)

Research and Nonresearch Industry Payments for COVID-19 mRNA Vaccines in the United States
por: Murayama, Anju, et al.
Publicado: (2023)

Improvement of otologic symptoms associated with mRNA COVID-19 vaccines with corticosteroid treatment
por: Ma, Marek
Publicado: (2023)

Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site
por: Myles, Ian A, et al.
Publicado: (2021)

Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection
por: Bongiovanni, Marco, et al.
Publicado: (2021)

The Implications of the Cloning of the XLA Gene
por: Flinter, F A, et al.
Publicado: (1993)

COVID-19 mRNA vaccine-associated encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: A case report
por: Asaduzzaman, Md, et al.
Publicado: (2022)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights
por: Selvaraj, Gurudeeban, et al.
Publicado: (2021)

Acute myocarditis following a third dose of COVID-19 mRNA vaccination in adults
por: Simone, Anthony, et al.
Publicado: (2022)

BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity
por: Vizcarra, Pilar, et al.
Publicado: (2021)

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
por: Zaqout, Ahmed, et al.
Publicado: (2021)

Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration
por: Desai, Aditya P., et al.
Publicado: (2021)

Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19
por: Brosh-Nissimov, Tal, et al.
Publicado: (2021)

Immune Response to COVID-19 mRNA Vaccine—A Pilot Study
por: Lange, Andrzej, et al.
Publicado: (2021)

Humoral response to mRNA‐based COVID‐19 vaccine in patients with immune thrombocytopenia
por: Mori, Akio, et al.
Publicado: (2022)

Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)
por: Welsh, Kerry J., et al.
Publicado: (2021)

SARS‐CoV‐2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID‐19 vaccination
por: Castruita, Jose Alfredo Samaniego, et al.
Publicado: (2023)

Serological response to a single dose of a SARS-CoV-2 mRNA vaccine
por: Ramos, Angélica, et al.
Publicado: (2021)

Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
por: Luczkowiak, Joanna, et al.
Publicado: (2022)

Healthcare workers benefit from second dose of COVID-19 mRNA vaccine: Effects of partial and full vaccination on sick leave duration and symptoms
por: Strum, Earl, et al.
Publicado: (2022)

Neutralizing activity and T Cell response after bivalent fifth dose of mRNA vaccine in person living with HIV
por: Vergori, Alessandra, et al.
Publicado: (2023)

Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients
por: Abbate, Antonio, et al.
Publicado: (2021)

Smoking habits predict adverse effects after mRNA COVID-19 vaccine: Empirical evidence from a pilot study
por: Ponticelli, D., et al.
Publicado: (2023)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

COVID-19 mRNA vaccine BNT162b2 induces autoantibodies against type I interferons in a healthy woman
por: Ning, Wangbin, et al.
Publicado: (2022)

Effectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric Population
por: Genç Bahçe, Yasemin, et al.
Publicado: (2023)

Acute Generalized Exanthematous Pustulosis in Close Temporal Association with mRNA-1273 Vaccine
por: MITRI, Fouad, et al.
Publicado: (2021)

Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines
por: Botton, Jérémie, et al.
Publicado: (2022)

Anti-spike protein antibody responses to BNT162b2 mRNA vaccine: A single-center survey in a COVID-19 non-epidemic area in Japan
por: Mokuda, Sho, et al.
Publicado: (2022)

Time and cost of administering COVID-19 mRNA vaccines in the United States
por: Yarnoff, Benjamin, et al.
Publicado: (2021)

Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study
por: Kontopoulou, Konstantina, et al.
Publicado: (2021)

Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study
por: Baldolli, Aurelie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8vk64phkvp4tbfd38qf52is5or